[Effect of Moristerol (anti-cholesterolemic agent) on benign prostatic hypertrophy].
Moristerol was orally administered in 20 cases of benign prostatic hypertrophy. One capsule of Moristerol contained 200 mg of soysterol . In all the cases, 9 capsules of Moristerol were given per day in three divided doses for 6 weeks. Clinical improvement was observed in 11 of the 20 cases (55%). It consisted mainly of subjective complaints such as improvement of dysuria, narrow and weak urinary stream and feeling of incomplete voiding. As objective findings, a statistically significant decrease of residual urine volume was noted after treatment, although shrinkage of the enlarged prostate was not clear upon palpation or roentgenography. In addition to the improvement of symptoms, serum lipid peroxide which might be considered to be a provocative cause of benign prostatic hypertrophy, was also significantly decreased by Moristerol administration. No marked side effects were seen in this study.
D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008055:Lipids / Q000097:blood; D008297:Male; D010840:Phytosterols / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy*
D000924:Anticholesteremic Agents; D008055:Lipids; D010840:Phytosterols; C033580:soysterol